Chemours is trading 13% down at $15.60 after missing Q2 2026 revenue and EPS expectations and issuing soft Q3 guidance.
- The company reported a large GAAP net loss for the second quarter, missing analyst estimates on both the top and bottom lines.
- Management's Q3 2026 outlook projects lower Adjusted EBITDA compared to Q2, citing persistent refrigerant inventory headwinds that are overshadowing growth in specialty markets.